Aprepitant Versus Hydroxyzine in Persistent Aquagenic Pruritus for Patients With Myeloproliferative Neoplasms

NCT03808805 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

63

Enrollment

OTHER

Sponsor class

Conditions

Myeloproliferative Disorder
Aquagenic Pruritus

Interventions

DRUG: Aprepitant 80 mg
DRUG: Hydroxyzine 25mg
DRUG: Placebo of Hydroxyzine
DRUG: Placebo of Aprepitant

Sponsor

University Hospital, Brest